Stock Traders Purchase High Volume of Hims & Hers Health Call Options (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 47,929 call options on the company. This represents an increase of approximately 59% compared to the typical volume of 30,093 call options.

Insider Buying and Selling

In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $487,789.12. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the sale, the insider now owns 169,935 shares in the company, valued at $3,935,694.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 650,659 shares of company stock worth $11,712,198. Corporate insiders own 17.71% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds and other institutional investors have recently modified their holdings of HIMS. Vanguard Group Inc. raised its stake in shares of Hims & Hers Health by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after buying an additional 136,907 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares in the last quarter. Farallon Capital Management LLC lifted its position in shares of Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Hims & Hers Health by 67.5% during the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after purchasing an additional 273,473 shares during the period. Finally, M&G Plc acquired a new stake in Hims & Hers Health during the 1st quarter worth about $8,232,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Stock Up 16.0 %

Shares of Hims & Hers Health stock traded up $3.30 during trading hours on Wednesday, hitting $23.94. 15,769,240 shares of the company’s stock traded hands, compared to its average volume of 8,489,850. Hims & Hers Health has a twelve month low of $6.58 and a twelve month high of $25.74. The stock has a 50 day simple moving average of $18.10 and a 200-day simple moving average of $18.19. The company has a market cap of $5.14 billion, a PE ratio of 297.04 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business’s revenue was up 77.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.04) EPS. As a group, equities research analysts predict that Hims & Hers Health will post 0.22 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on HIMS shares. Needham & Company LLC assumed coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a report on Wednesday, August 7th. Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Finally, TD Cowen increased their price objective on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $20.71.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.